GSK and Actelion - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 report featuring GlaxoSmithKline's $3.25 billion partnership with Actelion.Who: GlaxoSmithKline
With: Actelion
What: $3.25B partnership

Summary: In July, GlaxoSmithKline agreed top pay Acetlion â‚£150 million up front and up to â‚£415 million more depending on Phase III data for its insomnia drug almorexant. Actelion could get another â‚£2.7 billion in additional milestone payments based on almorexant results for insomnia and two other major indications. As part of the deal, GSK gets worldwide rights to the drug outside of Japan.

GSK and Actelion - Top 10 deals of 2008
Read more on

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.